Demographic and clinical characteristics of patients with sustained and switching treatments using biological and targeted synthetic disease-modifying antirheumatic drugs: A multicenter, observational cross-sectional study for rheumatoid arthritis

Basit Öğe Kaydı
dc.authorid0000-0002-5852-3854
dc.contributor.authorAtaman, Şebnem
dc.contributor.authorSunar, İsmihan
dc.contributor.authorBodur, Hatice
dc.contributor.authorAlkan Melikoğlu, Meltem
dc.contributor.authorÇay, Hasan Fatih
dc.contributor.authorÇapkın, Erhan
dc.contributor.authorAkgül, Özgür
dc.contributor.authorÇevik, Remzi
dc.contributor.authorGöğüş, Feride
dc.contributor.authorKamanlı, Ayhan
dc.contributor.authorYurdakul, Fatma Gül
dc.contributor.authorGürer, Gülcan
dc.contributor.authorYağcı, İlker
dc.contributor.authorRezvani, Aylin
dc.contributor.authorDuruöz, Mehmet Tuncay
dc.date.accessioned2022-12-27T07:29:03Z
dc.date.available2022-12-27T07:29:03Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Fizik Tedavi ve Rehabilitasyon Ana Bilim Dalı
dc.description.abstractIntroduction Rheumatoid arthritis is a chronic inflammatory disease with different disease activity grades. Several registries have been designed to determine the appropriate regimens of disease-modifying antirheumatic drugs to obtain sustained clinical remission. We examined epidemiological and clinical characteristics of rheumatoid arthritis patients using a clinical registry database (BioSTaR) and analyzed the differences in patients with sustained and switched therapies. Methods A multicenter, observational cross-sectional study for rheumatoid arthritis was performed between February 2019 and September 2020 using the BioStaR-RA registry. Demographic and clinical characteristics were prospectively recorded into a specifically designed electronic database. The patients were divided into three groups due to the heterogeneity of the study cohort. Patients were grouped as Group I (Initial; within the first 6 months of treatment with biological/targeted synthetic drugs), Group ST (Sustained Treatment; any first drug lasting for at least 6 months without any change), and Group S (Switch; any switching to another drug). Comparative analysis was performed between sustained treatment (Group ST) and drug switching (Group S) groups. Results The study included a total of 565 patients. The mean age was 53.7 +/- 12.8 years, and the majority were female (80.4%). There were 104, 267, and 194 patients in Groups I, ST, and S, respectively. Erosive arthritis and hematological extra-articular involvement were more frequently detected in Group S than Group ST (p = 0.009 and p = 0.001). The patients in Group S had significantly higher disease activity scores (DAS28-CRP, CDAI, and SDAI) (p = 0.025, p = 0.010, and p = 0.003). There were significantly more patients with moderate disease activity in Group S (p < 0.05). Conclusions The groups with sustained treatment and switching included patients with different disease activity status, although higher disease activity was determined in switchers. Overall, moderate disease activity and remission were the most common disease activity levels. Lower disease activity scores, lower hematologic manifestations, better functional status, and lesser radiographic damage are associated with sustained treatment.
dc.description.sponsorshipTurkish Medicine and Medical Devices Agency ; Ankara Numune Egitim ve Arastirma Hastanesien_US
dc.identifier.citationAtaman, Ş., Sunar, İ., Bodur, H., Alkan Melikoğlu, M., Çay, H. F., Çapkın, E. ... Duruöz, M. T. (2022). Demographic and clinical characteristics of patients with sustained and switching treatments using biological and targeted synthetic disease-modifying antirheumatic drugs: A multicenter, observational cross-sectional study for rheumatoid arthritis. Rheumatology and Therapy, 9(1), 223-241. https://doi.org/10.1007/s40744-021-00403-y
dc.identifier.doi10.1007/s40744-021-00403-y
dc.identifier.endpage241
dc.identifier.issn2198-6576
dc.identifier.issn2198-6584
dc.identifier.issue1
dc.identifier.pmid34850376
dc.identifier.scopus2-s2.0-85120360954
dc.identifier.scopusqualityQ2
dc.identifier.startpage223
dc.identifier.urihttps://doi.org/10.1007/s40744-021-00403-y
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10189
dc.identifier.volume9
dc.identifier.wos000723963100001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorRezvani, Aylin
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofRheumatology and Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectRheumatoid Arthritis
dc.subjectDiseasemodifying Antirheumatic Drugs
dc.subjectRegistries
dc.subjectTreatment Switching
dc.titleDemographic and clinical characteristics of patients with sustained and switching treatments using biological and targeted synthetic disease-modifying antirheumatic drugs: A multicenter, observational cross-sectional study for rheumatoid arthritis
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Rezvani-Aylin-2022.pdf
Boyut:
542.76 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu